Recent News
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Twelve patients with relapsed malignant pleural mesothelioma will be treated with intratumoral injections of MTG201, a replication incompetent adenovirus, modified by the insertion of the reduced expression in immortalized cells (REIC)/Dikkopf (Dkk)-3 gene, on Days 1, 8, 22, and 50. Patients will also receive every 4 weekly intravenous infusions of nivolumab, 480 mg, starting on Day 2. Safety and anti-tumor activity will be monitored at regular intervals throughout the study.
Peripheral Neuropathy Pain Reduced in Mesothelioma Patients
Avastin (bevacizumab) is a type of chemotherapy treatment that slows tumor growth by blocking the protein that is responsible for forming new blood vessels, which is what tumors need to…
Less than Half of Cancer Patients Eligible for Immunotherapy Treatments
In late 2017, the FDA approved Keytruda (pembrolizumab) as an immunotherapy treatment for cancer. It’s typically used to treat inoperable metastatic non-small cell lung cancer and melanoma but it has…
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
This is a dose escalation (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of Nap with durvalumab in subjects with selected advanced or metastatic solid tumors.
Potential New Treatment Acts as a Sealant for Pleural Mesothelioma Tumors
Pleural mesothelioma, caused by exposure to asbestos is a rare cancer – only 3,000 cases are diagnosed in the U.S. each year – but it is highly aggressive. There is…
Mesothelioma Patients Not Receiving Treatment Impacts Guidelines and Overall Survival
A mesothelioma diagnosis can be grim and have life-long impact on the patients and family. The aggressive nature and the late diagnosis of the disease make it difficult to treat.…
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in subjects with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design followed by a Phase 2 study.
First FDA Approved Treatment for Mesothelioma in 15 Years
In the Fall of 2018 scientists and researchers from Novocure, an oncology company that specializes in treating solid tumors, were hopeful their latest success with Tumor Treating Fields therapy would…
Currently Recruiting: Mesothelioma Clinical Trials
When it comes to effective mesothelioma treatments, options are unfortunately limited. There is no cure for mesothelioma and first line chemotherapy treatment Alimta, is no guarantee. Many who are suffering…
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
